Schizophrenia/Psychosis

Data presents opportunities to enhance care and improve treatment adherence.

Research explores the differences between new-onset psychosis in patients with infection versus healthy controls.

A look at the theme for the 2023 American Psychiatric Association Annual Meeting.

From the relationship between social media and self-diagnosis to the FDA approval of the first treatment for agitation associated with Alzheimer disease dementia, here are highlights from the week in Psychiatric Times.

Individuals with schizophrenia have experienced an increase in psychiatric, medical, and treatment risks because of the COVID-19 pandemic.

From new FDA treatment approvals to choosing the right levels of care in crisis stabilization units, here are highlights from the week in Psychiatric Times.

The risperidone formulation is the first FDA-approved treatment for this patient population to use technology enabling controlled release over time.

The experts weighed in on a wide variety of psychiatric issues for the April 2023 issue of Psychiatric Times.

From connections between bvFTD and primary psychiatric disorders to the impact of posttraumatic neuroendocrine dysfunction on recovery, here are highlights from the week in Psychiatric Times.

Aripiprazole will be the first 2-month LAI antipsychotic indicated for both the treatment of schizophrenia and the maintenance treatment of bipolar I disorder in the United States.

From eating disorders in entertainment to early intervention for schizophrenia, here are highlights from the week in Psychiatric Times.

What does cancer treatment mean for psychiatric treatment with clozapine?

What are the key diagnostic differences between schizophrenia and schizoaffective disorder?

Schizophrenia is one of the most recognized yet least understood chronic brain disorders.

What are some of the most important contemporary issues in schizophrenia and the ways research can inform exemplary clinical practice?

"It is amazing how much we know about the magnificent brain—and how much we have yet to learn."

Research investigated this association in a prospective cohort study.

From collaborative care for individuals with schizophrenia and COVID-19 to strategies for building patient rapport, here are highlights from the week in Psychiatric Times.

Recent research evaluated evenamide as an add-on to an antipsychotic for patients with treatment-resistant schizophrenia.

How can patient-centered, collaborative care help promote safety and stabilization in the treatment of patients with cooccurring diagnoses of schizophrenia and COVID-19?

Researchers investigated sleep disturbances in individuals at ultra-high risk of psychosis.

Catatonia is thought to be significantly underrecognized, and it is important to routinely screen for it among hospitalized patients. Here's how to recognize and treat.

Caffeine use is higher in smokers and in adults with serious mental illness. How does this impact patients with bipolar disorder and schizophrenia?

Although psychotherapy is a core treatment in psychiatry, it is currently underutilized in the management of schizophrenia.

There is very modest evidence that clozapine may be associated with improvement of catatonia.

"The history of medicine is rich in blaming the disease or the patient for 'untreatable' symptoms, until we stumble upon or develop a treatment that is, in fact, effective."

The experts weighed in on a wide variety of psychiatric issues for the January 2023 issue of Psychiatric Times.

Are you ready to understand how recovery-oriented cognitive therapy (CT-R) promotes wellness and empowerment for individuals experiencing serious mental health challenges? Check out this CME article.

From a new FDA approval to treating “New Year depression” in patients, here are highlights from the week in Psychiatric Times.

New approval for schizophrenia and bipolar I disorder.